Low dose endoluminal photodynamic therapy improves murine T cell-mediated colitis.

Authors:
L Favre, F Borle, D Velin, D Bachmann, H Bouzourene, G Wagnieres, H van den Bergh, P Ballabeni, T Gabrecht, P Michetti, S Schreiber, M-A Ortner
Year of publication:
2011
Volume:
43
Issue:
7
Issn:
0013-726X
Journal title abbreviated:
ENDOSCOPY
Journal title long:
Endoscopy
Impact factor:
5.634
Abstract: 
LDPDT improves murine T cell-mediated colitis, decreases the proinflammatory cytokines interleukin-6, interleukin-17, and interferon-gamma, and decreases the number of CD4 (+) T cells. No adverse events were observed. Therefore, this technique is now being evaluated in patients with inflammatory bowel disease.LDPDT improved the MEIC ( P = 0.011) and the histological score ( P = 0.025), diminished the expression indices of the proinflammatory cytokines, interleukin-6 ( P = 0.042), interleukin-17 ( P = 0.029), and interferon-gamma ( P = 0.014), decreased the number of mucosal CD4 (+) T cells, and increased the percentage of apoptotic CD4 (+) T cells compared with the disease control group. No local or systemic side effects occurred.The safety of LDPDT was first tested in BALB/c mice. Naïve T cells were used to induce colitis in mice with severe combined immunodeficiency, which were followed up endoscopically, and a murine endoscopic index of colitis (MEIC) was developed. The efficacy of LDPDT (10 J/cm (2); delta-aminolevulinic acid, 15 mg/kg bodyweight) was then tested on mice with moderate colitis, while a disease control group received no treatment. The MEIC, weight, length, and histology of the colon, cytokine expression indices, number of mucosal CD4 (+) T cells, percentage of apoptotic CD4 (+) T cells, body weight, and systemic side effects were evaluated.Low dose photodynamic therapy (LDPDT) may modify the mucosal immune response and may thus provide a therapy for Crohn''s disease. We evaluated the efficacy and safety of this technique in a murine T cell-mediated colitis model.